A double-blinded, placebo-controlled trial of modafinil for amphetamine withdrawal
Completed
- Conditions
- Amphetamine withdrawalMental Health - Addiction
- Registration Number
- ACTRN12606000272594
- Lead Sponsor
- Government Department of Health and Aging.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Meets the Diagnostic and Statistical Manual for Mental Disorders No. 4 (DSM-IV) diagnosis of current amphetamine dependence, Has used amphetamines in previous 48 hours, Is seeking treatment for amphetamine dependence, Is willing and able to give informed consent.
Exclusion Criteria
Currently dependent on other psychoactive drugs other than amphetamines, cannabis or nicotine, Has any significant unstable medical conditions, Is pregnant or breastfeeding, Is suffering from active psychosis or current major depression, Is diagnosed with attention deficit hyperactivity disorder or narcolepsy, Is known to have had an allergic reaction to modafinil previously, Has had treatment with dexamphetamine or modafinil in the previous month.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The two treatment groups will be compared for their symptoms of amphetamine withdrawal, including symptoms of depression and sleep disturbance, neuro-cognitive function, as well as any potential side effects from the medication. [These symptoms will be measured once a day, for the seven to ten day inpatient stay]
- Secondary Outcome Measures
Name Time Method 1. To gain an understanding of the natural history of psychostimulant withdrawal in an inpatient setting, focusing on severity and duration of symptoms.[This will be measured every day of the seven to ten day inpatient stay];2. To examine the impact of offering withdrawal medication (modafinil) on retention in withdrawal treatment.[Measured every day of the seven to ten day inpatient stay]